Efficacy of Posaconazole in a Murine Model of Systemic Infection by Saprochaete capitata | Zendy

Pamela Thomson | Zendy; Josep Guarro | Zendy; Emilio Mayayo | Zendy; Javier Capilla | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of Posaconazole in a Murine Model of Systemic Infection by Saprochaete capitata

Author(s) -

Pamela Thomson,

Josep Guarro,

Emilio Mayayo,

Javier Capilla

Publication year - 2015

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01140-15

Subject(s) - posaconazole , in vivo , neutropenia , histopathology , pharmacology , biology , medicine , microbiology and biotechnology , toxicity , pathology , antifungal , amphotericin b

The fungusSaprochaete capitata causes opportunistic human infections, mainly in immunocompromised patients with hematological malignancies. The best therapy for this severe infection is still unknown. We evaluated thein vitro killing activity and thein vivo efficacy of posaconazole at 5, 10, or 20 mg/kg twice a day (BID) in a murine neutropenic model of systemic infection withS. capitata by testing a set of six clinical isolates. Posaconazole showed fungistatic activity against all of the isolates tested. The different doses of the drug, especially the highest one, showed good efficacy, measured by prolonged survival, reduction of (1-3)-β-d -glucan levels in serum, tissue burden reduction, and histopathology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research